Should tamoxifen be used in breast cancer prevention?

Drug Safety

Volumn 27, Issue 13, 2004, Pages 979-989

  Kramer, Rita ^a   Brown, Powel ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; CELECOXIB; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; PLACEBO; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDICATION; DRUG SAFETY; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; META ANALYSIS; ONCOGENE; OVARY CANCER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ADULT; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TAMOXIFEN;

EID: 8444233937     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427130-00001     Document Type: Review

References (58)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2003. CA Cancer J Clin 2004; 54: 8-29
2. Vogel VG. Breast cancer risk: weaving facts into fabric. Breast Cancer Res Treat 1993; 28: 91-6
3. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-7
4. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88
6. IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-24
7. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300
8. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67
9. Powles T, Eeles R, Salmon A, et al. Update of the Royal Marsden Hospital tamoxifen breast cancer chemoprevention trial [abstract 375]. American Society of Clinical Oncology (ASCO); 2003 May 31-June 6; Chicago, 94
10. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003; 95: 160-5
11. Frykberg ER. Lobular carcinoma in situ of the breast. Breast J 1999; 5: 296-302
12. Shoker BS, Jarvis C, Sibson DR, et al. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999; 188: 237-44
13. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-42
14. Tan-Chiu E, Wang J, Costantino JP, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003; 95: 302-7
15. Tretli S. Height and weight in relation to breast cancer morbidity and mortality: a prospective study of 570,000 women in Norway. Int J Cancer 1989; 44: 23-30
16. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000; 26: 291-302
17. Easton D, Ford D, Bishop DT. et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56: 265-71
18. King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCAI and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-PI) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-6
19. Narod S, Brunet J-S, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study: Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356 (9245): 1876-81
20. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-42
21. Hutchins L, Green S, Ravdin P, et al. CMF versus CAF ± tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: update of tamoxifen results [abstract no. 1]. Breast Cancer Res Treat 1999; 57: 57
22. Allred D, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24 [abstract]. Breast Cancer Res Treat 2002; 76S: S36
23. National Cancer Institute, US National Institutes of Health. National Cancer Institute Publications Locator [online]. Available from URL: http://cissecure.nci.nihi/gov/ncipubs/default.asp [Accessed 2004 Aug 31]
24. US FDA. New drug application no. 17-970/S-040. Professional information brochure: Nolvadex® tarnoxifen citrate [online]. Available from URL: http://www.fda.gov/cder/foi/appletter/1998/17970s40.pdf [Accessed 2004 Aug 17]
25. Gail MH, Brinton L, Byar D, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-86
26. Anderson S, Anhnn S, Duff K. NSABP Breast Cancer Prevention Trial risk assessment program, version 2.: NSABP Biostatistical Center Technical Report. Pittsburgh (PA): Biostatistical Center NSABP, 1992
27. Costantino J, Gail M, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999; 91: 1541-8
28. Bondy M, Lustbader E, Halabi S, et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994; 86: 620-5
29. Spiegelman D, Colditz GA, Hunter DJ, et al. Validation of the Gail, et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994; 86: 600-7
30. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail, et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93: 358-66
31. Bondy M, Newman L. Breast cancer risk assessment models. Cancer 2002; 97: 230-5
32. Claus E, Risch N, Thompson W. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994; 73: 643-51
33. Domchek S, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003; 21: 593-601
34. Rubinstein W, O'Neill S, Peters J, et al. Mathematical modeling for breast cancer risk assessment: state of the art and role in medicine. Oncology (Huntingt) 2002; 16: 1082-94
35. Tyrer J, Duffy S, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23: 1111-30
36. Anderson G, Limacher M, Assaf A, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1769-71
37. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27
38. Rossouw JE, Anderson GL, Prentice RL, et al. 36. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
39. Day R, Ganz P, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17: 2659-69
40. Levine M, Moutquin J, Walton R, et al. Chemoprevention of breast cancer: a joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 2001; 164: 1681-90
41. US Preventive Services Task Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med 2002; 137: 56-8
42. Chelbowski R, Col N, Winer E, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20: 3328-43
43. National comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: v.1.2004 Breast Cancer Risk Reduction [online]. Available from URL: www.nccn.org/professionals/physician_gls/PDF/breast_risk.pdf [Accessed 2004 Aug 31]
44. Gail MH, Costantino J, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829-46
45. Hershman D, Sundararajan V, Jacobson J, et al. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 2002; 20: 9-16
46. Rutqvist LE, Johanson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995; 87: 645-51
47. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95: 779-90
48. Decensi A, Galli A, Veronesi U. HRT opposed to low-dose tamoxifen (HOT study): rationale and design. Recent Results Cancer Res 2003; 163: 104-11
49. Rotmensz N, Decensi A, Maisonneuve P, et al. Rationale for a study adding tamoxifen to HRT. Eur J Cancer 2002; 38: S22-3
50. Serrano D, Perego E, Costa A, et al. Progress in chemoprevention of breast cancer. Crit Rev Oncol Hematol 2004; 49: 109-17
51. Duggan C, Marriott K, Edwards R, et al. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003; 21: 3588-93
52. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-97
53. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial: multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-34
54. Rastogi P, Vogel VG. Update on breast cancer prevention. Oncology (Huntingt) 2003; 17: 799-805
55. Buzdar A, O'Shaughnessy J, Booser D, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003; 21: 1007-14
56. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802-10
57. Goss PE. Breast cancer prevention: clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003; 86: 487-93
58. Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004; 100: 1800-6